Harbin Pacific Biopharmaceutical

Harbin Pacific Biopharmaceutical is a prominent Chinese biopharmaceutical firm focused on the production of plasma-derived medicinal products. Founded in 1986 and headquartered in Harbin, the company manages a network of plasma collection centers and maintains large-scale GMP-certified manufacturing capabilities. Its core product line includes human albumin, intravenous immunoglobulin (IVIG), and specialized immunoglobulins for rabies, tetanus, and hepatitis B, as well as coagulation factors for hemophilia. Following its acquisition by Beijing Tiantan Biological Products (a Sinopharm subsidiary) in 2021, the company has become a key component of China's national blood products infrastructure.